ACE and COVID-19: Recent studies have reported that the application of ACE inhibitors can induce a marked increase in ACE2 expression, which means that ACEIs/ARBs would increase the risk of COVID-19 infection and disease aggravation of COVID-19 in hypertension and diabetes patients receiving these drugs35,36.